Premium
Ependymoblastoma associated with prenatal exposure to diphenylhydantoin and methylphenobarbitone
Author(s) -
Lipson Anthony,
Bale Patricia
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19850501)55:9<1859::aid-cncr2820550902>3.0.co;2-f
Subject(s) - transplacental , offspring , ornithine transcarbamylase deficiency , ornithine transcarbamylase , pregnancy , medicine , neuroblastoma , urea cycle , carcinogenesis , epilepsy , physiology , teratology , fetus , endocrinology , cancer , biology , genetics , psychiatry , amino acid , arginine , placenta , cell culture
Ependymoblastoma developed in a 28‐month‐old girl whose epileptic mother took diphenylhydantoin and methylphenobarbitone throughout pregnancy. The child was also shown to be a genetic carrier for ornithine transcarbamylase deficiency, an x‐linked inborn error of urea cycle metabolism. The possibility of transplacental carcinogenesis should be considered, as other juvenile embryonic tumors such as neuroblastoma, melanotic neuroectodermal tumor, and mesenchymoma have been reported in offspring after diphenylhydantoin use by the mother during pregnancy.